share_log

AbbVie | 8-K: AbbVie Reports Third-Quarter 2024 Financial Results

AbbVie | 8-K: AbbVie Reports Third-Quarter 2024 Financial Results

艾伯維公司 | 8-K：艾伯維公佈2024年第三季度財務業績
美股SEC公告 ·  2024/10/30 19:47

Moomoo AI 已提取核心訊息

On October 30, 2024, AbbVie Inc. reported its financial results for the third quarter ending September 30, 2024. The company announced a 3.8% increase in net revenues to $14.46 billion on a reported basis, and a 4.9% increase on an operational basis. Notably, the immunology portfolio contributed $7.046 billion, a 3.9% reported increase, with significant revenue from Skyrizi and Rinvoq. The oncology portfolio saw an 11.6% reported increase to $1.687 billion, while the neuroscience portfolio jumped 15.6% to $2.363 billion. However, the aesthetics portfolio experienced a slight decrease of 0.1% in revenues. AbbVie's GAAP diluted EPS was $0.88, a 12% decrease, while the adjusted diluted EPS was $3.00, a 1.7% increase. The company also completed the acquisition of Cerevel, enhancing its neuroscience portfolio, and raised its full-year adjusted diluted EPS guidance from $10.67 - $10.87 to $10.90 - $10.94. Additionally, AbbVie announced a 5.8% dividend increase to be paid in February 2025. CEO Robert A. Michael expressed confidence in the company's momentum and long-term growth outlook.
On October 30, 2024, AbbVie Inc. reported its financial results for the third quarter ending September 30, 2024. The company announced a 3.8% increase in net revenues to $14.46 billion on a reported basis, and a 4.9% increase on an operational basis. Notably, the immunology portfolio contributed $7.046 billion, a 3.9% reported increase, with significant revenue from Skyrizi and Rinvoq. The oncology portfolio saw an 11.6% reported increase to $1.687 billion, while the neuroscience portfolio jumped 15.6% to $2.363 billion. However, the aesthetics portfolio experienced a slight decrease of 0.1% in revenues. AbbVie's GAAP diluted EPS was $0.88, a 12% decrease, while the adjusted diluted EPS was $3.00, a 1.7% increase. The company also completed the acquisition of Cerevel, enhancing its neuroscience portfolio, and raised its full-year adjusted diluted EPS guidance from $10.67 - $10.87 to $10.90 - $10.94. Additionally, AbbVie announced a 5.8% dividend increase to be paid in February 2025. CEO Robert A. Michael expressed confidence in the company's momentum and long-term growth outlook.
2024年10月30日，艾伯維公司報告了截至2024年9月30日的第三季度財務業績。公司宣佈，按照報告基礎，淨營業收入增長了3.8%，達到144.6億美元，按照經營基礎增加了4.9%。值得注意的是，免疫學組合貢獻了70.46億美元，報告增長了3.9%，Skyrizi和Rinvoq帶來了可觀的營收。腫瘤學組合報告增長了11.6%，達到16.87億美元，而神經科學組合增長了15.6%，達到23.63億美元。然而，美學組合的營收略微下降了0.1%。艾伯維公司的美國通用會計準則攤薄後每股收益爲0.88美元，下降了12%，而調整後攤薄後每股收益爲3.00美元，增長了1.7%。公司還完成了對Cerevel的收購，增強其神經科學組合，並將全年調整後每股攤薄收益指導從10.67 - 10.87美元提高到了10.90 - 10.94美元。此外，艾伯維宣佈將於2025年2月支付5.8%的股息增加。首席執行官羅伯特·A·邁克爾對公司的勢頭和長期增長前景表示信懇智能。
2024年10月30日，艾伯維公司報告了截至2024年9月30日的第三季度財務業績。公司宣佈，按照報告基礎，淨營業收入增長了3.8%，達到144.6億美元，按照經營基礎增加了4.9%。值得注意的是，免疫學組合貢獻了70.46億美元，報告增長了3.9%，Skyrizi和Rinvoq帶來了可觀的營收。腫瘤學組合報告增長了11.6%，達到16.87億美元，而神經科學組合增長了15.6%，達到23.63億美元。然而，美學組合的營收略微下降了0.1%。艾伯維公司的美國通用會計準則攤薄後每股收益爲0.88美元，下降了12%，而調整後攤薄後每股收益爲3.00美元，增長了1.7%。公司還完成了對Cerevel的收購，增強其神經科學組合，並將全年調整後每股攤薄收益指導從10.67 - 10.87美元提高到了10.90 - 10.94美元。此外，艾伯維宣佈將於2025年2月支付5.8%的股息增加。首席執行官羅伯特·A·邁克爾對公司的勢頭和長期增長前景表示信懇智能。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間